Details of the Drug
General Information of Drug (ID: DMM1CKZ)
Drug Name |
3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
507268-13-5; CHEMBL365499; 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile; 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]Benzonitrile; 3-(5-(pyridin-2-yl)-2h-tetrazol-2-yl)benzonitrile; 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile; SCHEMBL660355; CTK1G6179; DTXSID70436690; OGIBYDWBTRKAOL-UHFFFAOYSA-N; ZINC3962980; BDBM50151907; AKOS015995227; RP28801; DA-05371; DB-050669; KB-233258; FT-0760671; J-510771; 3-[5-(2-Pyridinyl)-2H-tetrazole-2-yl]benzonitrile; Benzonitrile, 3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 248.24 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||